Unifying heterogeneous expression data to predict targets for CAR-T cell therapy

Chimeric antigen receptor (CAR) T-cell therapy combines antigen-specific properties of monoclonal antibodies with the lytic capacity of T cells. An effective and safe CAR-T cell therapy strategy relies on identifying an antigen that has high expression and is tumor specific. This strategy has been s...

Descripción completa

Detalles Bibliográficos
Autores principales: Schreiner, Patrick, Velasquez, Mireya Paulina, Gottschalk, Stephen, Zhang, Jinghui, Fan, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632331/
https://www.ncbi.nlm.nih.gov/pubmed/34858726
http://dx.doi.org/10.1080/2162402X.2021.2000109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632331/
https://www.ncbi.nlm.nih.gov/pubmed/34858726
http://dx.doi.org/10.1080/2162402X.2021.2000109

Ejemplares similares